NanoMed Pharmaceuticals Founders Issued Broad Patent for Novel Method to Make Nanoparticles Nanotemplate Engineering(TM) Being Used to Develop New AML Drug



    KALAMAZOO, Mich., Jan. 3 /PRNewswire/ -- NanoMed Pharmaceuticals, Inc.,
 an early-stage specialty pharmaceutical company dedicated to developing
 improved therapeutic and diagnostic products to treat or detect cancer and
 other serious diseases, announced today that founders Russell J. Mumper,
 Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525
 entitled "Microemulsions As Precursors To Solid Nanoparticles." Their
 invention, assigned to the University of Kentucky Research Foundation and
 licensed exclusively to NanoMed Pharmaceuticals, covers processes and
 applications of Nanotemplate Engineering, a nanoparticle manufacturing
 technology used to formulate small molecules, peptides, proteins, plasmid
 DNA, and diagnostic agents.
     Nanotemplate Engineering involves a rapid, reproducible, and scalable
 process to manufacture nanoparticles without the need to use expensive
 equipment commonly required to make other types of pharmaceutical delivery
 systems. "We created and developed an engineering process to make
 nanoparticles that literally takes minutes, and can involve simply mixing
 all of the ingredients and the drug in a single vessel," said Russell J.
 Mumper, Ph.D., Associate Professor and Vice Chair of the Department of
 Pharmaceutical Sciences in the College of Pharmacy at the University of
 Kentucky. "These nanoparticles can deliver proteins, diagnostic agents and
 other materials to specific tissues, cells and tumors," Mumper added.
     "Drs. Mumper and Jay have shown that these nanoparticles, when
 manufactured to contain anti-cancer drugs, can deliver the drug more
 effectively to cancer cells that have developed resistance to the drug when
 administered alone," said Stephen Benoit, NanoMed President and CEO. "Based
 on these data, NanoMed is utilizing Nanotemplate Engineering to develop its
 lead product which is intended to overcome multidrug resistance in
 remission induction therapy in elderly acute myelogenous leukemia (AML)
 patients," Benoit added. Currently, this lead product is in preclinical
 development and the company expects to begin safety and efficacy tests in
 AML patients in early 2008, working with Dianna S. Howard, M.D., Associate
 Professor, Blood and Marrow Transplant Program at the University of
 Kentucky Lucille P. Markey Cancer Center.
     NanoMed intends to expand its Nanotemplate Engineering product pipeline
 in 2007 to include the development of a second oncology drug targeted to
 overcome multidrug resistance. In addition, the company is exploring
 potential partnerships with pharmaceutical companies developing new drugs
 to overcome resistance in other types of cancer.
     The company's lead product incorporates a compound that is a proven
 anti- leukemic agent for the treatment of acute leukemias. Leukemia, a
 cancer of the bone marrow and blood characterized by the uncontrolled
 accumulation of immature blood cells, is primarily a disease of the elderly
 with the median age at diagnosis of 68 years. Leukemia that occurs in
 elderly AML patients is intrinsically resistant to chemotherapy and
 patients suffer inferior outcomes. Many elderly AML patients are not
 offered and/or refuse standard induction and post-remission therapy. Thus,
 an efficacious, relatively non-toxic approach is expected to be welcomed by
 patients and leukemia treatment specialists.
     NanoMed Pharmaceuticals(R), Inc. (www.nanomedpharm.com) is an
 early-stage specialty pharmaceutical company dedicated to developing
 improved therapeutic and diagnostic products to treat or detect cancer and
 other serious diseases. Nanotemplate Engineering is a nanoparticle
 manufacturing technology used to formulate small molecules, peptides,
 proteins, plasmid DNA, and diagnostic agents. The company is headquartered
 in Kalamazoo, Michigan with research and development operations located at
 the University of Kentucky's Advanced Science & Technology
 Commercialization Center (ASTeCC).
 
 

SOURCE NanoMed Pharmaceuticals(R), Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.